Guerbet's Elucirem™ Approved for Pediatric MRI with Half-Dose Gadolinium Use Guerbet's Elucirem™ (gadopiclenol) receives FDA approval for pediatric MRI use, including term neonates, with half the conventional gadolinium dosage.

Guerbet's Elucirem™ Approved for Pediatric MRI with Half-Dose Gadolinium Use #USA #Princeton #gadopiclenol #Guerbet #Elucirem

New Indication for Pediatric Use of Guerbet's Elucirem™ Approved by EU Commission Guerbet's Elucirem™ receives European Commission approval for pediatric MRI use, offering a reduced gadolinium dose for infants. A significant advancement in medical imaging.

New Indication for Pediatric Use of Guerbet's Elucirem™ Approved by EU Commission #France #gadopiclenol #Guerbet #Villepinte #Elucirem

Guerbet's Elucirem™ Secures EU Approval for Pediatric Use with Half-Dose Solution Guerbet has received European Commission approval for Elucirem™, a gadolinium-based contrast agent for infants, enabling half-dose MRIs while ensuring patient safety.

Guerbet's Elucirem™ Secures EU Approval for Pediatric Use with Half-Dose Solution #France #gadopiclenol #Elucirem™ #Guerbet #Villepinte

Guerbet's Elucirem™ Receives New Approval for Pediatric Use in Europe Guerbet announces the European approval of Elucirem™, a low-dose gadolinium contrast agent, now safe for infants and enhancing MRI imaging.

Guerbet's Elucirem™ Receives New Approval for Pediatric Use in Europe #None #gadopiclenol #Elucirem™ #Guerbet

European Commission Approves New Pediatric Indication for Elucirem™ (Gadopiclenol) from Guerbet Guerbet announces the European Commission's approval of a new pediatric indication for Elucirem™, enabling its safe use in infants for MRI procedures.

European Commission Approves New Pediatric Indication for Elucirem™ (Gadopiclenol) from Guerbet #France #gadopiclenol #Elucirem™ #Guerbet #Villepinte